|
Patient and caregiver benefit-risk preferences for treatment in advanced urothelial carcinoma. |
|
|
No Relationships to Disclose |
|
M. Janelle Cambron-Mellott |
Employment - Kantar Health |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - AstraZeneca; Takeda; Takeda |
Stock and Other Ownership Interests - Takeda |
|
|
Employment - Kantar Health |
Research Funding - AstraZeneca (Inst) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Other Relationship - AstraZeneca |
|
|
Employment - Kantar Health |
Research Funding - AstraZeneca (Inst) |
|
|
Employment - Kantar Health |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |